Emmaus Life Sciences 8/14/2025 Earnings Report

Emmaus Life Sciences EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Emmaus Life Sciences Revenue Results

• Actual Revenue: $2.82 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Emmaus Life Sciences Announcement Details

• Date: 8/14/2025
• Time: During Market Hours
• Conference Call Date: N/A
• Conference Call Time: N/A

Emmaus Life Sciences (OTCMKTS:EMMA) is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.

Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America. The company’s commercial strategy leverages partnerships for scalable manufacturing, regulatory support and local distribution capabilities. Beyond its lead therapy, Emmaus is evaluating early-stage assets to expand its portfolio in rare hematology, seeking to bring new treatment options to patients with unmet medical needs.

Founded in 2005 and headquartered in the San Francisco Bay Area, Emmaus Life Sciences is led by a management team with deep expertise in biotechnology, clinical development and regulatory affairs. The company collaborates with global research institutions and patient advocacy groups to support clinical trials, facilitate global access initiatives and ensure that emerging therapies reach underserved populations. Emmaus continues to pursue strategic alliances and licensing opportunities to drive the advancement of its product pipeline worldwide.